EA
VIRX

Edge Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Edge Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$0 Hold
1
– – ﹤0.01% 928
2018
Q1 		$0 Hold
1
– – ﹤0.01% 967
2017
Q4 		$0 Buy
+1
New +$94 ﹤0.01% 979

Other funds holding VIRX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Edge Advisors's VIRX Position: Q2 2018 in Review

Edge Advisors held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q2 2018 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #928.

Edge Advisors first reported a position in VIRX in Q4 2017 and has held it in 3 quarters since. 50 funds tracked by Wall St. Rank hold VIRX as of Q2 2018.

  • Edge Advisors held 1 share of Viracta Therapeutics, Inc. Common Stock worth $0 as of Q2 2018.
  • Edge Advisors left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q2 2018.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #928 holding.
  • Edge Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2017 and has held it in 3 quarters since.
  • 50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.